IC-MPGN clinical trials at UCSF

1 research study open to eligible people

IC-MPGN is a kidney disease that causes inflammation and damage to the kidney filters. UCSF is conducting a study to test the safety and effectiveness of a drug called Iptacopan for people with IC-MPGN. This trial includes different groups and compares the drug to a placebo.

Showing trials for

  • Iptacopan in Participants With IC-MPGN

    open to eligible people ages 12-60

    This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis.

    San Francisco, California and other locations

Last updated: